Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors
Early Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 42
- Registration Number
- NCT06713148
Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix.
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 79
- Registration Number
- NCT06705322
Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 180
- Registration Number
- NCT06703047
A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 22
- Registration Number
- NCT06699472
- Locations
- 🇨🇳
Fudan University Shanghai Cencer Center,, Shanghai, Shanghai, China
First-line Treatment of Advanced/unresectable DDLPS
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 49
- Registration Number
- NCT06694324
- Locations
- 🇨🇳
Fudan University, Cancer Hospital, Shanghai, Shanghai, China
Combination of Toripalimab and JS004 Therapy for ccRCC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT06690697
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Ivocizumab in the Treatment of Multiple Advanced Tumors
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT06683846
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer
Not yet recruiting
- Conditions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 6000
- Registration Number
- NCT06684418
A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 9
- Registration Number
- NCT06682117
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT06684327
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath